Investigational drug · Phase 2
CT1812
Also called: Study Drug Active
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Early Alzheimer's Disease, Dementia With Lewy Bodies.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
13
Any phase or sponsor naming "CT1812"
First trial start
2022
May 19, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CT1812", any sponsor or status.
Conditions studied
As listed on its trial records.
- Early Alzheimer's Disease
- Dementia With Lewy Bodies
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "CT1812" as an intervention, largest first.
- A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's DiseasePivotal-lookingActive, not recruiting
Cognition TherapeuticsIndustry
NCT05531656 · 540 participants (planned) · Start Jun 28, 2023 · Primary completion May 31, 2027
Drug: CT1812; Placebo · For: Early Alzheimer's Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Sun City, Arizona · 50 sites in all
- A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.Pivotal-lookingCompleted
Cognition TherapeuticsIndustry
NCT03507790 · 153 participants · Start Oct 10, 2018 · Primary completion May 29, 2024
Drug: CT1812; Placebo · For: Mild to Moderate Alzheimer's Disease
Sites: Phoenix, Arizona; Scottsdale, Arizona; Stamford, Connecticut · 32 sites in all
- Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy BodiesPivotal-lookingCompleted
Cognition TherapeuticsIndustry
NCT05225415 · 130 participants · Start May 19, 2022 · Primary completion Nov 25, 2024
Drug: CT1812 · For: Dementia With Lewy Bodies
Sites: Phoenix, Arizona; Sun City, Arizona; Tucson, Arizona · 34 sites in all
- Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).Pivotal-lookingTerminated
Cognition TherapeuticsIndustry
NCT05893537 · 100 participants · Start Jun 16, 2023 · Primary completion Mar 4, 2025
Drug: Active Comparator CT1812; Placebo Comparator · For: Age-Related Macular Degeneration
Sites: Phoenix, Arizona; Sacramento, California; Walnut Creek, California · 19 sites in all
Cognition TherapeuticsIndustry
NCT02570997 · 80 participants · Start Sep 2015 · Primary completion May 2016
Drug: CT1812; Placebo · For: Cognitive Impairment
Sites: Melbourne, Australia
Cognition TherapeuticsIndustry
NCT03493282 · 43 participants · Start Mar 28, 2018 · Primary completion Oct 16, 2020
Drug: Active Treatment- CT1812 100 mg; Active Treatment- CT1812 300 mg and 1 more · For: Alzheimer Disease
Sites: New Haven, Connecticut
Cognition TherapeuticsIndustry
NCT05248672 · 35 participants · Start Feb 15, 2022 · Primary completion Jun 1, 2022
Drug: CT1812 · For: Alzheimer Disease
Sites: DeLand, Florida
Cognition TherapeuticsIndustry
NCT02907567 · 19 participants · Start Sep 2016 · Primary completion Aug 24, 2017
Drug: CT1812; Placebo · For: Alzheimer's Disease
Sites: Southport, Australia; Ivanhoe, Australia; Melbourne, Australia · 4 sites in all
Cognition TherapeuticsIndustry
NCT04735536 · 16 participants · Start Jul 9, 2020 · Primary completion Apr 26, 2023
Drug: CT1812 · For: Alzheimer Disease
Sites: Amsterdam, Netherlands
Cognition TherapeuticsIndustry
NCT03716427 · 16 participants · Start Nov 10, 2016 · Primary completion Dec 27, 2016
Drug: CT1812; tolbutamide and 3 more · For: Healthy Volunteers
Sites: Kalamazoo, Michigan
Newest research
PubMed records naming it or its code names, newest first.
- TMEM97 links endoplasmic reticulum stress to hepatic stellate cell activation in experimental liver fibrosis: pharmacological attenuation by CT1812.
Li J, Liu W, Zhang H, et al. · Eur J Pharmacol 2026
- Crystal Structure of the Sigmaߛ2 Receptor Complexed with Investigational Drug Zervimesine (CT1812).
Look GC, Gilzer D, Preuss F, et al. · ACS Med Chem Lett 2026
- CT1812 Attenuates Surgery-Induced Cognitive Impairment and Modulates TMEM97- and PGRMC1-Associated Hippocampal Stress Responses in Aged Mice.
Wang Q, Wei Y, Shen C, et al. · Neurochem Res 2026
- Randomized, double-blind study of zervimesine in mild to moderate Alzheimer's disease.
Vijverberg EGB, Scharre DW, Woodward M, et al. · J Alzheimers Dis 2026
- Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer's disease.
Di Caro V, Cho E, Thiel J, et al. · Alzheimers Res Ther 2026
- Phase 2 study of zervimesine (CT1812) in participants with mild-to-moderate dementia with Lewy bodies (DLB).
Galvin JE, Tolea MI, Scharre DW, et al. · Alzheimers Dement 2025
Also in development for Early Alzheimer's Disease
- SemagludtidePhase 32 trials
Lumos Pharma · Obesity & Overweight, Early Alzheimer's Disease
- MK-2214Phase 21 trial
Merck & Co. · Early Alzheimer's Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.